{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:45:46Z","timestamp":1770133546078,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11845-016-1470-2","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T16:03:45Z","timestamp":1465315425000},"page":"161-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Fumaric acid esters for psoriasis: a systematic review"],"prefix":"10.1007","volume":"186","author":[{"given":"D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","volume":"30","author":"PJ Altmeyer","year":"1994","unstructured":"Altmeyer PJ, Matthes U, Pawlak F et al (1994) Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30:977\u2013981","journal-title":"J Am Acad Dermatol"},{"key":"1470_CR2","first-page":"223","volume":"3","author":"D Barth","year":"2011","unstructured":"Barth D, Simon JC, Wetzig T (2011) \u2018Malignant melanoma during treatment with fumaric acid esters\u2014coincidence or treatment related? JDDG. J der Deutschen Dermatologischen Gesellschaft 3:223\u2013224","journal-title":"J der Deutschen Dermatologischen Gesellschaft"},{"key":"1470_CR3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2230.2007.02389.x","volume":"32","author":"L Brewer","year":"2007","unstructured":"Brewer L, Rogers S (2007) Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 32:246\u2013249","journal-title":"Clin Exp Dermatol"},{"key":"1470_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09546630310019346","volume":"15","author":"I Carboni","year":"2004","unstructured":"Carboni I, De Felice C, De Simoni I et al (2004) Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatol Treat 15:23\u201326","journal-title":"J Dermatol Treat"},{"issue":"17","key":"1470_CR5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB (2013) PML in a patient treated with fumaric acid. N Engl J Med 368(17):1657\u20131658","journal-title":"N Engl J Med"},{"issue":"5","key":"1470_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00128071-200506050-00002","volume":"6","author":"DA Fairhurst","year":"2005","unstructured":"Fairhurst DA, Ashcroft DM, Griffiths EM (2005) \u2018Optimal Management of Severe Plaque Form of Psoriasis. Am J Clin Dermatol 6(5):283\u2013294","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1470_CR7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2005.07103.x","volume":"154","author":"Z Fika","year":"2006","unstructured":"Fika Z, Williams REA, Williamson DJ (2006) Fumaric acid esters in psoriasis. Br J Dermatol 154(3):567\u2013568","journal-title":"Br J Dermatol"},{"key":"1470_CR8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2005.06728.x","volume":"153","author":"MJ Harries","year":"2005","unstructured":"Harries MJ, Chalmers RJG, Griffiths CEM (2005) Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 153:549\u2013551","journal-title":"Br J Dermatol"},{"key":"1470_CR9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2230.2012.04351.x","volume":"37","author":"K Heelan","year":"2012","unstructured":"Heelan K, Markham T (2012) Fumaric acid esters as a suitable first line treatment for severe psoriasis: an Irish experience. Clin Exp Dermatol 37:786\u2013801","journal-title":"Clin Exp Dermatol"},{"key":"1470_CR10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","volume":"149","author":"JJ Hoefnagel","year":"2003","unstructured":"Hoefnagel JJ, Thio HB, Willemze R et al (2003) Long term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149:363\u2013369","journal-title":"Br J Dermatol"},{"key":"1470_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjd.12849","volume":"171","author":"N Ismail","year":"2014","unstructured":"Ismail N, Collins P, Rogers S et al (2014) Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol 171:397\u2013402","journal-title":"Br J Dermatol"},{"key":"1470_CR12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1468-3083.2009.03234.x","volume":"23","author":"L Jennings","year":"2009","unstructured":"Jennings L, Murphy GM (2009) Squamous cell carcinoma as a complication of fumaric acid ester immunosuppression. Eur Acad Dermatol Venereol 23:1445\u20131469","journal-title":"Eur Acad Dermatol Venereol"},{"key":"1470_CR13","doi-asserted-by":"crossref","unstructured":"Kolbach DN, Niebor C (1992) \u2018Fumaric acid therapy in psoriasis: Results and side effects of 2\u00a0years of treatment\u2019. J Am Acad Dermatol 27(5 part 1): 769\u2013771","DOI":"10.1016\/S0190-9622(08)80228-9"},{"key":"1470_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2133.1999.03034.x","volume":"141","author":"U Mrowietz","year":"1998","unstructured":"Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 141:424\u2013429","journal-title":"Br J Dermatol"},{"key":"1470_CR15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2133.2005.06563.x","volume":"152","author":"L Naldi","year":"2005","unstructured":"Naldi L, Griffiths CEM (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597\u2013615","journal-title":"Br J Dermatol"},{"issue":"2","key":"1470_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(08)80766-9","volume":"22","author":"WM Nugteren-Huying","year":"1990","unstructured":"Nugteren-Huying WM, van der Schroeff JG, Hermans J et al (1990) Fumaric acid therapy for psoriasis: a randomised, double blind, placebo controlled study. J Am Acad Dermatol 22(2):311\u2013312","journal-title":"J Am Acad Dermatol"},{"key":"1470_CR17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2230.2011.04047.x","volume":"36","author":"S Ogilvie","year":"2011","unstructured":"Ogilvie S, Lewis Jones S, Dawe R et al (2011) Proteinuria with fumaric acid ester treatment for psoriasis. Clin Exp Dermatol 36:632\u2013634","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1470_CR18","first-page":"5","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P et al (2009) \u2018European S3- Guidelines on the systemic treatment of psoriasis vulgaris. Eur Acad Dermatol Venereol 23(2):5\u201370","journal-title":"Eur Acad Dermatol Venereol"},{"key":"1470_CR19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1191\/096032799678839662","volume":"18","author":"C Raschka","year":"1999","unstructured":"Raschka C, Koch HJ (1999) Long term treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 18:738\u2013739","journal-title":"Hum Exp Toxicol"},{"key":"1470_CR20","first-page":"603","volume":"7","author":"K Reich","year":"2009","unstructured":"Reich K, Thaci D, Mrowietz U et al (2009) Efficacy and safety of fumaric acid esters in the long term treatment of psoriasis- a retrospective study (FUTURE). JDDG. J der Deutschen Dermatologischen Gesellschaft 7:603\u2013610","journal-title":"JDDG. J der Deutschen Dermatologischen Gesellschaft"},{"issue":"1","key":"1470_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.12380","volume":"169","author":"C Reid","year":"2013","unstructured":"Reid C, Holian J, Kane D et al (2013) De Toni Fanconi Syndrome secondary to fumaric acid esters. Br J Dermatol 169(1):24","journal-title":"Br J Dermatol"},{"key":"1470_CR22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"J Schmitt","year":"2008","unstructured":"Schmitt J, Zhang Z, Wozel G et al (2008) Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate to severe psoriasis: meta-analysis of randomised controlled trials. Br J Dermatol 159:513\u2013526","journal-title":"Br J Dermatol"},{"key":"1470_CR23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2133.2006.07435.x","volume":"155","author":"MJ Sladden","year":"2006","unstructured":"Sladden MJ, Osborne JE, Hutchinson PE (2006) Fumaric acid esters for severe psoriasis: the Leicestershire experience. Br J Dermatol 155:841\u2013865","journal-title":"Br J Dermatol"},{"key":"1470_CR24","first-page":"439","volume":"1610\u20130379","author":"D Tha\u00e7i","year":"2013","unstructured":"Tha\u00e7i D, Weisenseel P, Philipp S et al (2013) \u2018Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions \u2013 a retrospective evaluation (FACTS). J Ger Soc Dermatol 1610\u20130379:439\u2013445","journal-title":"J Ger Soc Dermatol"},{"issue":"17","key":"1470_CR25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"BW Oosten Van","year":"2013","unstructured":"Van Oosten BW, Killestein J, Barkhof F et al (2013) PML in a patient treated with dimethylfumarate from a compounding pharmacy. N Engl J Med 368(17):1658\u20131659","journal-title":"N Engl J Med"},{"key":"1470_CR26","first-page":"373","volume":"7","author":"Y Wu","year":"2008","unstructured":"Wu Y, Mills D, Bala M (2008) Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7:373\u2013377","journal-title":"J Drugs Dermatol"},{"key":"1470_CR27","unstructured":"European Medicines Agency (2015). \u2018Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera\u2019. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2015\/10\/WC500196017.pdf . Accessed Mar 1, 2016"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-016-1470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-016-1470-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-016-1470-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-016-1470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:54:14Z","timestamp":1498319654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-016-1470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s11845-016-1470-2","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}